Drug Resistance of Tuberculosis Patients in Huizhou

Objective To analyze the drug resistance of tuberculosis patients in Huizhou,to realize its level and trend. Methods From January 2009 to May 2014,1 018 tuberculosis patients were chosen in Department of Tuberculosis in our institute,including 1 020 newly treated patients( newly treated group),790 retreated patients( retreated group). Strains of all patients were collected and then given 11 kinds of drugs for sensitivity test in vitro,including isoniazid( INH,H),streptomycin( SM, S), rifampicin( RFP, R), ethambutol( EMB, E), kanamycin( KM), amikacin( AM), capreomycin( CM),levofloxacin( LOF),ofloxacin( OFX),4- amino salicylic acid( PAS),propylthiouracil isonicotinoyl amine( TH1321),and drug resistance were analyzed. Results In the 1 810 tuberculosis patients,the resistant rate of the first-line anti- tuberculosis drugs was 50. 8%( 920 /1 020),the resistant rate of the second- line anti- tuberculosis drugs was 20. 3%( 367/1 020). The MDR rate 〔7.2%( 73/1 020) 〕and resistant rates of 7 kinds of second- line anti- tuberculosis drugs〔20. 2%( 206/1 020) 〕of newly treated group were lower than those of retreatment group 〔31. 1%( 246/790),20. 4%( 161/790) 〕( P 0.05). Tuberculosis patients with MDR had higher initial resistant rates and acquired resistant rates of S,E,and lower re- sensitive rates; lower initial resistant rates and acquired resistant rates of AM,CM,PAS,TH1321,and higher re- sensitive rates; higher retreated resistant rates of KM,LOF,OFX. Conclusion THE first- line anti- tuberculosis drug resistant rates of tuberculosis patients in Huizhou are high,which need to be further strengthen to the prevent and control the drug- resistant tuberculosis. Retreated tuberculosis patients had a remainly higher drug resistance,which should pay more attention to,including clinical management and treatment. AM,CM,PAS,TH1321 are recommended for the treatment of multi-drug resistant tuberculosis patients. Monitoring the drug resistance of multi- drug resistant tuberculosis patients and timely updating the overall data is helpful to make individual treatment plans,and to reduce extensively drug- resistant tuberculosis( XDR- TB).